NCT07728383RecruitingPhase 4
A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Topical-Lingual Semaglutide (T-L Semaglutide) in Adults With Obesity
Source: ClinicalTrials.gov · Last updated 27 Jul 2026
Brief summary (registry, in English)
This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general. GLP-1 is a gut-derived hormone that induces satiation through hypothalamic pathways.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 17 Apr 2026
- Start date
- 17 Jun 2026
- Primary completion date
- May 2027
- Lead sponsor
- Gila Therapeutics, Inc.
- Diseases
- Obesity
- NCT number
- NCT07728383
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 40
- From 17 Jun 2026 to the primary completion date, May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Type 2 Diabetes Mellitus
- Medullary thyroid cancer
Other
- Multiple Endocrine Neoplasia Type 2
Who the study is looking for
- Body Mass Index 30 to 45
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinical Research Institute of Minnesota Coordinator of this site? Confirm its status | Minneapolis | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.